Aug 26, 2011
Acquisition Complements Baxter’s Broad Nutrition and Drug Delivery Portfolio
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) announced today that it has entered into a definitive agreement to acquire Baxa Corporation, a privately held company based in Englewood, Colo., with additional operations in Florida and the United Kingdom. Baxa develops pharmacy technology that enhances the efficiency and safety of oral and IV dose preparation and delivery. The addition of Baxa’s product lines will complement Baxter’s portfolio of nutrition products and drug delivery systems and supports patient safety.
“With these new offerings, Baxter will be able to provide a comprehensive solution to fulfill the majority of patients’ nutritional requirements and increase efficiency in the pharmacy,” said Robert M. Davis, president of Baxter’s Medical Products business. “Bringing this expertise together with Baxter’s commercial capabilities and global reach will enable us to continue to meet our customers' evolving needs and extend our position in IV nutrition and fluid delivery.”
The transaction includes a total upfront cash consideration of $380 million and is expected to close following satisfaction of customary closing conditions and the expiration or early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. Annual sales for Baxa were approximately $150 million in 2010, and Baxter expects the future top-line growth of this business to be accretive to the company’s future sales growth. In addition, Baxter expects this transaction to be neutral to full-year 2012 earnings excluding dilution of approximately $0.03 to $0.05 per diluted share related to acquisition accounting and transaction-related expenses, and increasingly accretive thereafter.
Nutrition is recognized as an important element of patients’ therapy, and both Baxter and Baxa have sought to advance the delivery of IV nutrition through innovative technologies such as Baxter’s multi-chamber, premixed containers and Baxa’s automated compounding systems.
Baxter’s multi-chamber containers are prefilled and provide many of the essential ingredients of balanced nutrition for a wide range of patients. Baxa’s pharmacy integration and automation technology allow hospital pharmacists to customize treatment for specific patient populations when needed.
In response to the growing need to eliminate sources of potential error, both premixed medications and pharmacy automation help to reduce medication errors and improve operational effectiveness. Among Baxa’s numerous offerings are the ExactaMix® Compounder, devices that automate multi-ingredient nutritional solution compounding and the DoseEdge® Pharmacy Workflow Manager, an integrated system for managing IV and oral dose preparation activities.
Baxa products play a trusted role in the preparation of hundreds of thousands of safe doses of medication every day. “With this agreement, Baxa will be able to play a greater role in delivering safe medication practices,” said Greg Baldwin, Baxa chairman and chief executive officer. “We are very pleased to find a partner that shares our commitment and sees the potential in our products, technology and people.”
About Baxter’s Medical Products Business
Baxter’s Medical Products business develops and provides products used in the delivery of fluids and drugs to patients. These include IV solutions and administration sets, premixed drugs and drug-reconstitution systems, IV nutrition products, infusion pumps, inhalation anesthetics and products and services for people with end-stage kidney disease. At the forefront of IV nutrition, Baxter’s ongoing advancements include multi-chamber containers, lipids, amino acids, vitamins and admixing technology.
Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.
This release includes forward-looking statements concerning a definitive agreement entered into between the company and Baxa, including expectations with respect to the closing of the transaction and its financial impact on the company. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; changes in laws and regulations; product quality or patient safety issues; failure to obtain the necessary consents or to satisfy other closing conditions; and other risks identified in the company's most recent filing on Form 10-K and other SEC filings, all of which are available on the company's website. The company does not undertake to update its forward-looking statements.
Baxter International Inc.
Christy Noland, (847) 948-4380
Deborah Spak, (847) 948-2349
Mary Kay Ladone, (847) 948-3371
Clare Trachtman, (847) 948-3085
|Jan 16, 2019||Helmer Scientific Launches the First Professional Medical-grade Refrigerators|
|Jan 11, 2019||CORE Higher Education Group partners with Pharmacists Mutual|
|Jan 08, 2019||Tutela Welcomes the Center for Organ Recovery and Education|
|Dec 13, 2018||PharmaLink Launches Updated Website|
|Dec 11, 2018||Jorgenson Issues Annual List of Major Challenges Facing Hospital and Health Syst...|
|Nov 29, 2018||BD Expands Integrated Medication Management to Help Tackle Hospital Drug Diversi...|
|Nov 13, 2018||Akro-Mils 2019 Catalog|
|Nov 13, 2018||New Data Shows Many Health System Pharmacies Considering Consolidated Distributi...|
|Oct 17, 2018||Retail Management Solutions Celebrates 20 Years of Pharmacy POS Innovation|
|Oct 17, 2018||Hardy Diagnostics Releases a New Locking Lid Feature for all Contact Plates|
|Oct 15, 2018||Transaction Data Systems Partners with Community Pharmacies to Fight the Opioid ...|
|Oct 12, 2018||1st Patient-Centered Respiratory Home™ Accreditation Recipient Named|
|Oct 10, 2018||Augusta University Health Selects Omnicell’s Industry-Leading Medication Manag...|
|Oct 04, 2018||QS/1® Honors Pharmacists at NCPA|
|Oct 03, 2018||Innovation to Move to New Campus in New York’s Southern Tier to Accommodate St...|
|Oct 03, 2018||Equashield and Max Care Medical to Distribute Leading Closed System Transfer Dev...|
|Oct 01, 2018||Global Needlefree Closed System Transfer Device (CSTD) Market 2018 by Manufactur...|
|Sep 23, 2018||Prudential Overall Supply Celebrates Dan Clark's 50th Employment Anniversary|
|Sep 19, 2018||RXQ Compounding Expanding in Albany|
|Sep 17, 2018||Middlesex Hospital Bolsters Pharmacy Safety and Compliance by Extending Wolters ...|
|Sep 14, 2018||Synergy Medical once again among Canada's Top 500 Companies|
|Sep 10, 2018||American Associated Pharmacies Taps FDS to Bring its Members a State-of-the-Art ...|
|Sep 10, 2018||Rees Scientific achieved ISO/IEC 17025:2017 Accreditation|
|Sep 06, 2018||Medical Packaging Inc. Named One of The Best Places to Work In New Jersey|
|Sep 06, 2018||Americorp Financial Launches New Brand, Website for Equipment Financing|
|Sep 04, 2018||Excelera® Specialty Pharmacy Network Announces Partnership with Smith & Nephew|
|Aug 30, 2018||Letco Medical, L.L.C. Announces Exclusive Partnership with Sweetgrass GxP Group,...|
|Aug 29, 2018||QS/1® Selected as Early Adopter in New CMS SCRIPT Standard|
|Aug 23, 2018||Innovations to Omnicell Patient Engagement Platform Support Value-Based, Patient...|
|Aug 14, 2018||ACHC and ExceleraRx Corp. Form Partnership|
Connect with thousands of pharmacy professionals throughout every practice setting.